About US
Contact us
-
IRS alleges Bristol Myers dodged $1.38B in taxes with offshore patent scheme: reportWall Street analyst Tim Anderson is known for asking tough questions during pharma companies’ earnings calls, so it may not have seemed surprising when he brought up Bristol Myers Squibb’s massive dr2021/3/29
-
Pharma Pfizer, BioNTech eye full FDA approval for COVID-19 vaccine as efficacy stands strong, including against aggressive variantPfizer and BioNTech offered an updated look at the efficacy of their COVID-19 vaccine, BNT162b2. The overall efficacy figure remained high at 91.3%, and the shot showed it can protect against a notor2021/3/29
-
AbbVie says biosim maker Alvotech recruited a manufacturing exec to steal trade secrets on HumiraAs AbbVie braces for biosimilar competition to its top drug Humira, the company is takingbiosimsmakerAlvotech to taskin court over alleged trade secrets theft. In a newlawsuitfiled in Illinois, AbbVi2021/3/25
-
GSK cuts ties with Slaoui over sexual harassment allegations as CEO Walmsley vows to rename R&D siteMoncef Slaoui, Ph.D., attracted both acclaim and controversy during his time as co-leader of the U.S. government’s Operation Warp Speed effort to speed COVID-19 vaccines to market. Now, he’s facing s2021/3/25
-
Fierce Pharma Asia—Pfizer's China biosim retreat; WuXi Bio's buying spree; Fujifilm's $2B plantPfizer is retreatingfromChina's biosimilar market, ending development of three programs and selling a biologics plant pegged to make them to WuXi Biologics. In addition to the Pfizer deal, the Chines2021/3/23
-
Incyte, Novartis aim to make Jakafi available in severe COVID-19 after narrow trial missOver the span of more than a year during the pandemic, pharma companies of all stripes have tested their existing medicines against COVID-19. Incyte is one of them. Unfortunately, Incyte’s Jakafi fel2021/3/23
-
Challenging AbbVie and Lilly in psoriatic arthritis, J&J touts 2-year data for TremfyaWhen Johnson & Johnson scored approval for Tremfya inpsoriatic arthritis last year, the company set outin crowded field withentrenched competition. But now thedrugmakerhasnew long-term datato bol2021/3/18
-
In wake of biopharma mega buyouts, FTC kicks off review of industry's dealmakingBristol Myers Squibb and Celgene. AbbVie and Allergan. Pfizer's Upjohn unit and generics giant Mylan. These arethree of the biggest pharma mergers of the past couple years. They're also the kind of d2021/3/18
-
Specialty drugmaker ANI to boost CDMO work, generics portfolio with $210M Novitium buyoutSpecialty drugmaker ANI Pharmaceuticals has been steadily growing its generics arsenal over the past decade while also striving to expand itsCDMO business. Now, the company has inkeda deal to fuel bo2021/3/16
-
Pfizer's COVID-19 vaccine faced EMA manufacturing concerns ahead of emergency nod: reportAbout a month before Pfizer and BioNTech won an emergency nod for theirCOVID-19 vaccine in Europe, regulators raised flags about lower-than-expected levelsof intact mRNAin commercial batches, the BMJ2021/3/16